Please make sure that HealthWell currently has a fund for your diagnosis/indication and that your medication is covered under that fund by visiting our Disease Funds listing. If we do not have a fund that currently covers your diagnosis, please check back as we frequently open and reopen programs as funding becomes available. The Foundation is able to help patients receiving treatment for indications for which we currently have an open fund. We can only assist with medications that have been prescribed to treat the disease/covered diagnosis. You will be asked to provide the Foundation with the patient’s diagnosis, which must be verified by a physician, nurse practitioner, or physician assistant’s signature. The patient must receive treatment in the United States.
Giant Cell Arteritis or Temporal Arteritis - Medicare Access (Medicare patients only)
Status
ClosedThis fund is temporarily closed to new patients due to lack of sufficient funding. Please continue to visit our Disease Funds page often, as replenished funds reopen as quickly as possible. If you currently have a grant with HealthWell, your grant will remain active for the entire 12 month grant cycle or until you have exhausted your allocated grant amount, whichever comes first. You can continue to use your pharmacy card or submit requests for reimbursements during your designated grant cycle.
Fund Type
CopayPremium (Medicare Part B only)
Maximum Award Level
Pharmacy Card Fund
YesMinimum CopayReimbursement Amount
We encourage you to please use your HealthWell pharmacy card for any applicable charges as possible.
Minimum Premium
Reimbursement Amount
Household Income Limit
400% of the Federal Poverty Level(adjusted for household size and high
cost of living areas)
Treatments Covered
- Actemra
- Arze-ject-a
- Arzerra
- Beta 1 Kit
- Beta-phos/ac
- Betameth Com
- Betameth Pf
- Celestone
- Deltasone
- Depo-medrol
- Dex La
- Dexamet/nacl
- Dexamethasone
- Dexamethasone Phosphate
- Dexamethasone Sodium Phosphate
- Dexpak
- Doubledex
- Kenalog-10
- Kenalog-40
- Locort
- Marbeta-l
- Maxidex
- Medrol
- Methylpr Ss
- Methylprd Pf
- Methylpred
- Methylpred Ace
- Millipred
- Millipred Dp
- Orapred Odt
- Ozurdex
- P-care D40
- P-care D80
- P-care K40
- P-care K40g
- P-care K80
- P-care K80g
- Pediapred
- Pod-care 100
- Pod-care100c
- Pred Sod Pho
- Prednisolone
- Prednisone
- Pro-c-dure 5
- Pro-c-dure 6
- Rayos
- Ready Betame
- Ready Dexame Kit
- Ready Methyl
- Ready Triamc
- Readysharp +
- Solu-cortef
- Solu-medrol
- Tofidence
- Triamcinolone
- Triesence
- Triloan Ii
- Triloan Suik
- Veripred 20
- Zonacort
Fund Definition
Assistance with the prescription drugs and biologics used in the treatment of giant cell arteritis or temporal arteritis.
Grant Utilization
HealthWell estimates that patients use an average of $3,590 during their 12-month grant period for this disease area.
Do I Qualify?
HealthWell bases eligibility on an individual’s medical, financial and insurance situation. To qualify for HealthWell’s assistance, applicants must meet the following eligibility requirements:
-
-
This is a Medicare Access Fund. In order to qualify for premium assistance through this fund, you must have Medicare Part B. The Foundation will refer patients without Medicare to other programs, such as manufacturer patient assistance programs.
-
HealthWell assists individuals with incomes up to 300-500% of the Federal Poverty Level. The Foundation also considers the number in a household and cost of living in a particular city or state. If you believe you qualify for assistance, you may begin the application process here.
-
If you are receiving treatment in the U.S. and have met the eligibility criteria as listed, you are ready to apply! Please note that you will be asked to provide a Social Security Number in order to create a grant. This information is gathered to eliminate duplicate applications and is kept secure and confidential.
About Giant Cell Arteritis
Giant cell arteritis (GCA), also known as temporal arteritis, is an autoimmune disease and a form of vasculitis. Autoimmune diseases are conditions in which immune cells, which normally help fight infections, are misdirected to attack healthy tissues. In the case of GCA, these immune cells are involved in an inflammatory reaction in large arteries of the body, which damages the blood vessel branches of the aorta and often the aorta itself. The inflammation in GCA can cause swelling of the blood vessel wall and narrowing of the blood vessel lumen, causing decreased blood supply to the neighboring tissues. The blood vessel may also become thrombosed (clotted), causing severe ischemia or necrosis of tissues ordinarily supplied by the blood vessel. According to the Vasculitis Foundation, it has been estimated that 228,000 Americans have GCA. Source: Vasculitis Foundation
Additional Educational Resources
You may also visit our Resource List to view other copayment organizations that may provide assistance.
